Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  March 29th, 2018 , 4:30 p.m. ET CORALVILLE, Iowa , March 21, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,
Toggle Summary KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD
Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations CORALVILLE, Iowa , March 20, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and
Toggle Summary KemPharm to Present at Upcoming Investor Conferences
Presentations to Highlight Corporate and Clinical Progress CORALVILLE, Iowa , March 06, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive
Toggle Summary KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain
Apadaz is the First Prodrug of Hydrocodone/Acetaminophen to be Approved by FDA Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 2:30 p.m. ET CORALVILLE, Iowa , Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company
Toggle Summary KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference
Corporate Updates and Clinical Progress to be Highlighted CORALVILLE, Iowa , Feb. 13, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the Company’s
Toggle Summary KemPharm to Present at The MoneyShow Orlando Investor Conference
CORALVILLE, Iowa , Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C.
Toggle Summary KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone
Additional Patent Granted for the KP511-related family, a Prodrug of Hydromorphone CORALVILLE, Iowa , Jan. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today
Toggle Summary KemPharm Initiates Pivotal Efficacy Trial of KP415
‘Classroom-style’ Pivotal Efficacy Trial of ADHD Prodrug Composition Candidate  to Study Onset and Duration of Efficacy and Product Safety Screening commenced in November; first patient treatment occurred December 20, 2017 CORALVILLE, Iowa , Jan. 08, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate,  Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa , Nov. 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company
Toggle Summary KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD Methylphenidate Prodrug Product Candidate --  KP484 IND Review Completed by FDA ; Cleared to Proceed to Clinical